Virginia Venture Partners, the equity investment program of Virginia Innovation Partnership Corporation (VIPC), today announced an investment in Manassas, Va.-based Jeeva. Jeeva provides a scalable eClinical Software as a Service (SaaS) platform that helps sponsors and contract research organizations (CROs) accelerate flexible clinical operations while minimizing burden on site staff and patients. Jeeva will use this investment towards commercialization of the SaaS platform to accelerate therapy development for therapeutic areas such as rare diseases, immunology, and oncology in the U.S. and in emerging markets such as Latin America and India, where the company has recently established strategic partnerships.
Like many other industry sectors, the bioscience space has been slow to embrace the digital future. Investing in and building out an integrated, enterprise-wide digital platform always played second fiddle to funding R&D, hiring, manufacturing and the commercial function. A Deloitte “Perspectives” piece perhaps framed the current state of digital transformation in the life sciences best, suggesting that organizations need to move “…from merely doing digital to being digital” or risk irrelevancy.
Maximizing Clinical Trial Access, Diversity, and Efficiency are Keys to Optimizing Orphan Drug Development
Developing new orphan therapies, increasing access to existing life-saving treatments, and lowering costs is a moral imperative. However, major challenges remain for the rare disease community to achieve these goals.
MANASSAS, Va. (PRWEB) February 14, 2022 — As the number of pediatric clinical trials show signs of improvement, how to best sustain and scale them comes into play. Dr. Harsha Rajasimha of Jeeva Informatics addresses the challenges in making radical improvements in pediatric CT operations.
TYSONS CORNER, Va. (PRWEB) September 20, 2021 — Clinical trials of new drugs and treatments have a high failure rate. Better planning and technology-aided communication, says Dr. Harsha Rajasimha of Jeeva Informatics, can significantly reduce the number of participants who drop out, thus improving the chances of success—for the trials and the therapeutic product itself.
In recognition of Rare Disease Day 2021, Jeeva Informatics (Jeeva) brought together a panel of experts to discuss the importance of transforming the clinical trial process for rare diseases. The panel included Annie Kennedy, Chief of Policy and Advocacy, EveryLife Foundation for Rare Diseases; Thomas Lester, Former Executive Director, Audentes Therapeutics; Scott Schliebner, Senior Vice President, Scientific Affairs & Therapeutic Expertise, PRA Health Sciences; and Dr. Eric Sid, Program Director, National Center for Advancing Translational Science, Office of Rare Disease Research, (NCATS)/NIH.
This Startup is on a Mission to Decentralize Cell and Gene Therapy Clinical Trials For the cell and gene therapy revolution to be fully realized, physicians, research scientists, biomanufacturing experts, [….]
In Conversation: Dr. Harsha K. Rajasimha, IndoUSrare BioBuzz recently sat down for a conversation with Dr. Harsha K. Rajasimha, a leading rare disease advocate, the founder of the non-profit, IndoUSrare, [….]